Merck's sprifermin meets in Phase II for OA

Merck KGaA (Xetra:MRK) reported data from the Phase II FORWARD trial to treat osteoarthritis (OA) of the knee showing that sprifermin (AS902330) met the primary endpoint, suggesting that the candidate could be a disease-modifying treatment for the indication.

Read the full 383 word article

User Sign In